Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)
NCT ID: NCT01967732
Last Updated: 2020-03-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
62 participants
INTERVENTIONAL
2013-11-30
2014-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)
NCT01967719
Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)
NCT01959607
Exploratory THS 2.1 Nicotine Pharmacokinetics and Safety Study
NCT01780688
Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol).
NCT01967706
Nicotine Pharmacokinetics of THS Single Use of a Regular or a Menthol Stick Compared to CIG
NCT05789420
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
THS 2.2 then CC
Each subject will follow the below study design:
* Day 0 = Wash-out (1 day)
* Day 1 = 1st intervention (single product use of THS 2.2)
* Day 2 = wash-out
* Day 3 = 2nd intervention (single product use of CC).
THS 2.2
Single use of the Tobacco Heating System 2.2 (THS 2.2)
CC
Single use of subject's own conventional cigarette (CC)
CC then THS 2.2
Each subject will follow the below study design:
* Day 0 = Wash-out (1 day)
* Day 1 = 1st intervention (single product use of CC)
* Day 2 = wash-out
* Day 3 = 2nd intervention (single product use of THS 2.2).
THS 2.2
Single use of the Tobacco Heating System 2.2 (THS 2.2)
CC
Single use of subject's own conventional cigarette (CC)
THS 2.2 then NNS
Each subject will follow the below study design:
* Day 0 = Wash-out (1 day)
* Day 1 = 1st intervention (single product use of THS 2.2)
* Day 2 = wash-out
* Day 3 = 2nd intervention (single administration of NNS)
THS 2.2
Single use of the Tobacco Heating System 2.2 (THS 2.2)
NNS
Single administration of 1 mg of nicotine
NNS then THS 2.2
Each subject will follow the below study design:
* Day 0 = Wash-out (1 day)
* Day 1 = 1st intervention (single administration of NNS)
* Day 2 = wash-out
* Day 3 = 2nd intervention (single product use of THS 2.2).
THS 2.2
Single use of the Tobacco Heating System 2.2 (THS 2.2)
NNS
Single administration of 1 mg of nicotine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
THS 2.2
Single use of the Tobacco Heating System 2.2 (THS 2.2)
CC
Single use of subject's own conventional cigarette (CC)
NNS
Single administration of 1 mg of nicotine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Smoking, healthy subject as judged by the Investigator.
* Subject has smoked at least 10 commercially available non menthol CCs per day (no brand restrictions) for the last 4 weeks.
* Subject has smoked for at least the last 3 consecutive years.
* Subject does not plan to quit smoking in the next 3 months.
Exclusion Criteria
* Subject has received medication within 14 days or within 5 half-lives of a drug (whichever is longer) which has an impact on CYP2A6 activity.
* Female subject is pregnant or breast feeding.
* Female subject does not agree to use an acceptable method of effective contraception.
21 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Philip Morris Products S.A.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christelle Haziza, PhD
Role: STUDY_CHAIR
Philip Morris Products S.A.
Adrian Johnston Stewart, MD
Role: PRINCIPAL_INVESTIGATOR
Celerion GB Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Celerion GB Ltd, 22-24 Lisburn Road
Belfast, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZRHR-PK-01-EU
Identifier Type: OTHER
Identifier Source: secondary_id
2013-003097-27
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
ZRHR-PK-01-EU
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.